Setup Menus in Admin Panel

Digital therapeutics for overburdened healthcare systems

  • Edit Column
  • Edit Text Editor

While the term digital therapeutic may sound futuristic, these therapies are already a reality. As this new category of medicine continues to be integrated across healthcare ecosystems, digital therapeutics will increasingly influence the way healthcare is delivered and consumed across the world. Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioral conditions. I will explain what these DTx products are, where they are being used, how they are regulated in the EU. Afterwards, we can have a short brainstorm session on where they may be applicable to the patient journey at the Bellvitge University Hospital.




Jessica G. Shull
Bellvitge University Hospital, L’Hospitalet de Llobregat, Spain

Jessica Shull serves as the European Lead for the Digital Therapeutics Alliance. She is also project manager on clinical trials and big data projects for respiratory disease at the Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat. She worked 11+ years with the World Health Organization (WHO) on digital health projects for health system strengthening and production of educational materials for control of H1N1 and Ebola. Consultancies include World Bank, mHealth app evaluation guidelines for Europe, and EU regulatory process for digital diagnostics. She has an MS from the Medical College of Georgia, GA, USA, an MA form the University of Trento, Italy, and is currently pursuing a PhD in BioMedicine at the University of Barcelona.


© 2021 Bellvitge Biomedical Research Institute. All rights reserved.